Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ORPH

Orphazyme A/S (ORPH) Stock Price, News & Analysis

Orphazyme A/S logo

About Orphazyme A/S Stock (NASDAQ:ORPH)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$0.57
$2.21
52-Week Range
N/A
Volume
941,400 shs
Average Volume
1.37 million shs
Market Capitalization
$30.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

Remove Ads
Receive ORPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orphazyme A/S and its competitors with MarketBeat's FREE daily newsletter.

ORPH Stock News Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
See More Headlines

ORPH Stock Analysis - Frequently Asked Questions

Orphazyme A/S (ORPH) raised $100 million in an IPO on Tuesday, September 29th 2020. The company issued 7,600,000 shares at a price of $13.13 per share. BofA Securities, Cowen and Guggenheim Securities acted as the underwriters for the IPO and Danske Markets was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Orphazyme A/S investors own include AMC Entertainment (AMC), Digital World Acquisition (DWAC), NIO (NIO), Biora Therapeutics (BIOR), SNDL (SNDL), Tesla (TSLA) and Brigham Minerals (MNRL).

Company Calendar

Today
4/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ORPH
Fax
N/A
Employees
141
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.74 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$30.72 million
Optionable
Not Optionable
Beta
1.68
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ORPH) was last updated on 4/5/2025 by MarketBeat.com Staff
From Our Partners